Translating preclinical insights into effective human trials in ALS
- 31 December 2006
- journal article
- review article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1762 (11-12), 1139-1149
- https://doi.org/10.1016/j.bbadis.2006.03.007
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Metabolomic analysis and signatures in motor neuron diseaseMetabolomics, 2005
- ALSFRS‐RAmyotrophic Lateral Sclerosis, 2004
- Mutant dynactin in motor neuron diseaseNature Genetics, 2003
- From chemical to drug: neurodegeneration drug screening and the ethics of clinical trialsNature Neuroscience, 2002
- Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS)Brain Research, 1995
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994
- Parvalbumin and calbindin D‐28k in the human motor system and in motor neuron diseaseNeuropathology and Applied Neurobiology, 1993
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Progressive neuronopathy in transgenic mice expressing the human neurofilament heavy gene: A mouse model of amyotrophic lateral sclerosisCell, 1993
- Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosisNature, 1993